NO962348L - C5a reseptorantagonister uten agonist aktivitet - Google Patents

C5a reseptorantagonister uten agonist aktivitet

Info

Publication number
NO962348L
NO962348L NO962348A NO962348A NO962348L NO 962348 L NO962348 L NO 962348L NO 962348 A NO962348 A NO 962348A NO 962348 A NO962348 A NO 962348A NO 962348 L NO962348 L NO 962348L
Authority
NO
Norway
Prior art keywords
analogs
derivatives
receptor antagonists
human
activity
Prior art date
Application number
NO962348A
Other languages
English (en)
Other versions
NO962348D0 (no
Inventor
Jan Van Oostrum
William C Boyar
Nicholas G Galakatos
Jane V Peppard
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO962348D0 publication Critical patent/NO962348D0/no
Publication of NO962348L publication Critical patent/NO962348L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Polypeptidanaloger av human C5a som er C5a reseptorantagonister som utviser vesentlig ingen analfylatoksin eller agonistisk aktivitet, og derivater av analogene, og dimeriske former av analogene eller derivatene, er beskrevet. DNA molekyler som koder for polypeptidene og fremgangsmåter for fremstilling av analogene er også beskrevet. Farmasøytiske formuleringer inneholdende en C5a analog blir anvendt terapeutisk for behandling av C5a-formidlede sykdommer og inflammatoriske tilstander i pattedyr, og profylaktisk for å forhindre eller redusere inflammasjon forårsaket av en heneldse som forårsaket inflammasjon eller forverrer en eksisterende inflammatorisk tilstand. Antistoffer spesifikke for C5a analoger, derivater derav og dimerer av anlogene og derivater som utviser vesentlig ingen kryss-reaktivitet med human C5a er også beskrevet. Antistoffene blir anvendt for å detektere eller kvantifisere sirkulerende C5a analog eller derivat og også modifisere, for eksempel nøytralisere aktiviteten til C5a reseptorantagonisten in vivo.
NO962348A 1993-12-06 1996-06-05 C5a reseptorantagonister uten agonist aktivitet NO962348L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16259193A 1993-12-06 1993-12-06
PCT/IB1994/000359 WO1995016033A1 (en) 1993-12-06 1994-11-16 C5a RECEPTOR ANTAGONISTS HAVING SUBSTANTIALLY NO AGONIST ACTIVITY

Publications (2)

Publication Number Publication Date
NO962348D0 NO962348D0 (no) 1996-06-05
NO962348L true NO962348L (no) 1996-08-05

Family

ID=22586301

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962348A NO962348L (no) 1993-12-06 1996-06-05 C5a reseptorantagonister uten agonist aktivitet

Country Status (15)

Country Link
EP (1) EP0733107A1 (no)
JP (1) JPH09506258A (no)
CN (1) CN1142854A (no)
AU (1) AU698919B2 (no)
BR (1) BR9408265A (no)
CA (1) CA2176825A1 (no)
FI (1) FI962319A0 (no)
HU (1) HUT75990A (no)
IL (1) IL111792A0 (no)
MX (1) MXPA99008669A (no)
NO (1) NO962348L (no)
NZ (1) NZ274917A (no)
TW (1) TW429262B (no)
WO (1) WO1995016033A1 (no)
ZA (1) ZA949647B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837499A (en) * 1993-12-06 1998-11-17 Ciba-Geigy Corporation DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same
WO1996039503A1 (en) * 1995-06-05 1996-12-12 Novartis Ag C5a RECEPTOR ANTAGONISTS HAVING SUBSTANTIALLY NO AGONIST ACTIVITY AND METHODS FOR PREPARATION
CN1087572C (zh) * 1995-12-13 2002-07-10 北方电讯网络有限公司 集成蜂窝话音和数字分组数据电信系统及该系统的运行方法
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
TWI767415B (zh) * 2020-11-18 2022-06-11 中國醫藥大學 自動化血液分析系統及自動化血液分析方法
CN113150106B (zh) * 2021-04-26 2022-08-16 华中农业大学 来源于补体成分C5a的抗菌肽及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305615A1 (en) * 1987-09-03 1989-03-08 Immunetech Pharmaceuticals, Inc. Peptide antagonists for the C5a anaphylatoxin
JP2703764B2 (ja) * 1986-04-28 1998-01-26 シータス オンコロジー コーポレイション 補体成分Ｃ５ａに対するモノクローナル抗体

Also Published As

Publication number Publication date
BR9408265A (pt) 1996-12-10
JPH09506258A (ja) 1997-06-24
EP0733107A1 (en) 1996-09-25
IL111792A0 (en) 1995-01-24
FI962319A (fi) 1996-06-03
CN1142854A (zh) 1997-02-12
NO962348D0 (no) 1996-06-05
FI962319A0 (fi) 1996-06-03
MXPA99008669A (es) 2004-09-01
WO1995016033A1 (en) 1995-06-15
CA2176825A1 (en) 1995-06-15
TW429262B (en) 2001-04-11
HU9601538D0 (en) 1996-07-29
AU698919B2 (en) 1998-11-12
AU8002594A (en) 1995-06-27
NZ274917A (en) 1998-03-25
HUT75990A (en) 1997-05-28
ZA949647B (en) 1995-06-06

Similar Documents

Publication Publication Date Title
Perlstein et al. Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo
Lenczowski et al. Central administration of rat IL-6 induces HPA activation and fever but not sickness behavior in rats
Kruse et al. Conversion of human interleukin‐4 into a high affinity antagonist by a single amino acid replacement.
Moser et al. Interleukin-8 antagonists generated by N-terminal modification.
Capuron et al. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy
Sleeman et al. The ciliary neurotrophic factor and its receptor, CNTFRα
Al‐Humidan et al. Interleukin‐6 does not stimulate bone resorption in neonatal mouse calvariae
Yang et al. Annexin A1: potential for glucocorticoid sparing in RA
Kashem et al. G protein coupled receptor specificity for C3a and compound 48/80-induced degranulation in human mast cells: roles of Mas-related genes MrgX1 and MrgX2
Calandra et al. Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system
Konno et al. Crotalphine, a novel potent analgesic peptide from the venom of the South American rattlesnake Crotalus durissus terrificus
Michibata et al. Autocrine/paracrine role of adrenomedullin in cultured endothelial and mesangial cells
WO2014007547A1 (en) Novel peptides and use thereof
DK203489D0 (da) Anti-t-celle receptor determinanter til diagnosticering og behandling af autoimmune sygdomme
US20050013814A1 (en) Methods for treating rheumatoid arthritis using IL-17 antagonists
Rauner et al. Advances in osteoimmunology: pathophysiologic concepts and treatment opportunities
EP0743955A1 (en) Nerve growth factor structural analogs and their uses
Ievoli et al. Implication of the oligomeric state of the N-terminal PTX3 domain in cumulus matrix assembly
PT585681E (pt) Utilizacao do receptor de il-4 para terapia, profilaxia e diagnostico de doencas infecciosas
Bierl et al. ‘Mature’nerve growth factor is a minor species in most peripheral tissues
KR20180107368A (ko) Atpif1을 함유하는 당뇨 치료용 약학조성물
Hühner et al. Interleukin-4 protects dopaminergic neurons in vitro but is dispensable for MPTP-induced neurodegeneration in vivo
NO962348L (no) C5a reseptorantagonister uten agonist aktivitet
Pasquin et al. Cytokines of the LIF/CNTF family and metabolism
Prinz et al. β-adrenergic receptor stimulation selectively inhibits IL-12p40 release in microglia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application